Results 11 to 20 of about 67,015 (304)

Hypertrophic obstructive cardiomyopathy [PDF]

Annals of Cardiothoracic Surgery, 2017
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness ≥15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. Typical symptoms include dyspnoea, chest pain, palpitations, and syncope.
Christopher, Harris, Beth, Croce, Stine, Munkholm-Larsen   +2 more
openaire   +4 more sources

Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Objective: Atrial fibrillation is the most prevalent persistent arrhythmia in patients with hypertrophic obstructive cardiomyopathy. Comparative analyses of the safety and effectiveness of septal myectomy with and without surgical ablation are limited ...
Yanhai Meng, Yanbo Zhang, Ping Liu, Changsheng Zhu, Tao Lu, Enci Hu, Qiulan Yang, Changrong Nie, Shuiyun Wang   +8 more
doaj   +1 more source

Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A 20-Year Single-Center Experience

Anatolian Journal of Cardiology, 2022
Background: Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment.
Umut Karabulut, Yeşim Yılmaz Can, Egemen Duygu, Dilay Karabulut, Kudret Keskin, Tuğrul Okay   +5 more
doaj   +1 more source

Echocardiography for hypertrophic obstructive cardiomyopathy

Annals of Cardiac Anaesthesia, 2017
Kalpna Irpachi, K Ashok Kumar, Poonam Malhotra Kapoor   +2 more
doaj   +3 more sources

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal of the American College of Cardiology
S. M. Hegde, B. Claggett, Xiaowen Wang, K. Jering, N. Prasad, F. Roshanali, A. Masri, M. Nassif, R. Barriales-Villa, T. Abraham, Nuno Cardim, C. Coats, Christopher M. Kramer, M. Maron, Michelle Michels, I. Olivotto, S. Saberi, D. Jacoby, S. Heitner, S. Kupfer, L. Meng, A. Wohltman, F. Malik, Scott D. Solomon   +23 more
semanticscholar   +2 more sources

Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Circulation: Cardiovascular Interventions, 2013
Hypertrophic cardiomyopathy (HCM) is a common, yet challenging condition for clinical management. The majority of these patients have evidence of left ventricular outflow tract (LVOT) obstruction that may be asymptomatic or associated with debilitating symptoms of heart failure.
Paul, Sorajja, Steve R, Ommen, Rick A, Nishimura   +2 more
openaire   +2 more sources

Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited.
Sri Harsha Patlolla, Hartzell V. Schaff, Rick A. Nishimura, Mackram F. Eleid, Jeffrey B. Geske, Steve R. Ommen   +5 more
doaj   +1 more source

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

European Heart Journal, 2023
Graphical Abstract Graphical Abstract The path to treatment of obstructive hypertrophic cardiomyopathy. (Top left) Haemodynamic observations demonstrated. Left ventricular (LV) obstruction and symptoms related to LV hypertrophy.
E. Braunwald, S. Saberi, T. Abraham, Perry M. Elliott, I. Olivotto   +4 more
semanticscholar   +1 more source

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

Nature Communications, 2021
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients.
Bradley A. Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G. Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S. Huggins, Andriy O. Samokhin, William M. Oldham, Yasmine Aguib, Magdi H. Yacoub, Ethan J. Rowin, Barry J. Maron, Martin S. Maron, Joseph Loscalzo   +14 more
doaj   +1 more source

Exercise and hypertrophic cardiomyopathy: Two incompatible entities? [PDF]

, 2020
A greater understanding of the pathogenic mechanisms underpinning hypertrophic cardiomyopathy (HCM) has translated to improved medical care and better survival of affected individuals.
Basu, J, Malhotra, A, Papadakis, M
core   +1 more source